Biomedicine entered the 3.0 era, the first CSCO-Ding Oncology Summit Forum was held in Beijing.

"In recent years, the innovation ability of China's biopharmaceutical industry has been greatly enhanced, and biomedicine has entered the 3.0 era of open innovation, which provides new opportunities for the development of China's oncology sector." Professor Li Jin, chairman of the Chinese Society of Clinical Oncology (CSCO) and affiliated with Tongji University Oriental Hospital, said.On August 23,
, the "First CSCO-Reding Oncology Summit Forum" was held in Beijing, jointly organized by the Chinese Society of Clinical Oncology (CSCO) and Reding Pharmaceuticals. More than 300 experts and scholars from the field of clinical oncology from home and abroad gathered in Beijing to discuss the current situation and cutting-edge innovations in cancer diagnosis and treatment in China, including ovarian cancer and brain tumors.
Since the 1990s, China's pharmaceutical industry has experienced a leap from the 1.0 era dominated by imitation to the beginning of the 2.0 era of independent research and development. Driven by a series of policies to encourage innovation, the rise of local biopharmaceutical strength, more and more enterprises to join the ranks of international innovation biomedicine, open a high degree of participation in the global innovation system, open China's biopharmaceutical innovation 3.0 era.Yang Yang, of the China Biotechnology Development Center of the Ministry of Science and Technology of the
, said: "In recent years, China's research capacity in the field of biomedicine has been significantly improved, some technologies have taken the lead in achieving breakthroughs, but they still face problems such as weak basic research, low mastery of core technology, and lack of large pharmaceutical companies with strong international competitiveness." In the future, we need to strengthen deployment in key areas of strategic security, national economy and people's livelihood, and further increase the initiative of development and innovation.
currently, more than 700 new drugs are being developed in the late stages of development for cancer therapy. From 2013 to 2017, 63 NAS (new active substances) were approved for cancer therapy worldwide. Currently, patients in only nine countries around the world can buy more than half of the new drugs that have been on the market in the last five years.
"Under the institutional changes that encourage innovation, the development of Biomedicine in China is ushering in the best development opportunities." As the world's second largest clinical oncology group organization, the Chinese Clinical Oncology Association should play its own field expertise, to promote the academic exchange of clinical tumors, promote the popularization of new treatment strategies, which is our original intention to hold this CSCO-Ding Oncology Summit Forum. Professor Li Jin said, "Reding as a representative force in the era of biopharmaceutical innovation 3.0, the introduction of foreign best technology and independent research and development of a combination of two-wheel drive model can enable more patients to continue to benefit." In the future, we hope to work together with Reding to contribute to the development of the tumor industry. As the pioneer and leader of the chinese era of pharmaceutical innovation 3.0, "
" will give full play to its advantages and become an important bridge connecting China with the rest of the world in the exchange of medical technology achievements. "We hope to work with the government, clinical experts and other partners to fill the gap between China's cancer treatment and international first-class level with the shortest time, the fastest speed and the least amount of input, so that innovative cancer drugs can benefit Chinese patients and help the early realization of the strategic goal of 'Healthy China'," said Liang Yi, Chief Commercial Officer and President of Greater China. " (Ko Xiaoxuan)
.